New drug aims to help tiniest babies absorb nutrients safely
NCT ID NCT05904626
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tests whether a new medicine called ELGN-2112 is safe for very premature babies (born before 26 weeks) and for growth-restricted babies born between 26 and 32 weeks. About 60 infants will receive either the medicine or a placebo. The goal is to see if the drug can help with nutrient absorption problems without causing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTESTINAL MALABSORPTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Laniado Hospital
RECRUITINGNetanya, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.